Literature DB >> 27459024

Recombinant human granulocyte macrophage colony stimulating factor (hGM-CSF): Possibility of nanoparticle-mediated delivery in cancer immunotherapy.

Selvarajan Vanitha1, Nidhi Chaubey1, Siddhartha S Ghosh1,2, Pallab Sanpui2.   

Abstract

Most of the cancer treatment strategies from chemotherapy to radiotherapy render cancer cells apoptotic and these apoptotic cancer cells accumulate at the tumor sites. The accumulation of apoptotic cancer cells often result in inflammation and autoimmune responses causing serious health implications. Macrophages, which are effective immune combatants, can help in the clearance of these deleterious occupants. Granulocyte macrophage colony stimulating factor (GM-CSF) is a key cytokine, modulator of immune system and responsible for growth and differentiation of granulocytes and macrophages. In this regard, supply of recombinant GM-CSF can enhance the capability of macrophages for clearance of apoptotic cancer cells. However, delivery of the cytokine in vivo can suffer from certain disadvantages like faster depletion, less stability and low targeting efficiency. We believe that the stability and sustained release of GM-CSF can be improved through its encapsulation inside appropriately designed nanoparticles.

Entities:  

Keywords:  apoptosis; cancer immunotherapy; granulocyte macrophage colony stimulating factor; macrophages; nanoparticles; sustained release

Mesh:

Substances:

Year:  2016        PMID: 27459024      PMCID: PMC5398574          DOI: 10.1080/21655979.2016.1212136

Source DB:  PubMed          Journal:  Bioengineered        ISSN: 2165-5979            Impact factor:   3.269


  28 in total

Review 1.  Phagocytosis of apoptotic cells and the resolution of inflammation.

Authors:  Paola Maderna; Catherine Godson
Journal:  Biochim Biophys Acta       Date:  2003-11-20

Review 2.  Solid lipid nanoparticles as a drug delivery system for peptides and proteins.

Authors:  António J Almeida; Eliana Souto
Journal:  Adv Drug Deliv Rev       Date:  2007-05-01       Impact factor: 15.470

Review 3.  Nanocomposite Hydrogels: 3D Polymer-Nanoparticle Synergies for On-Demand Drug Delivery.

Authors:  Sonia Merino; Cristina Martín; Kostas Kostarelos; Maurizio Prato; Ester Vázquez
Journal:  ACS Nano       Date:  2015-05-12       Impact factor: 15.881

Review 4.  Recent advances in cancer therapy: an overview.

Authors:  A Urruticoechea; R Alemany; J Balart; A Villanueva; F Viñals; G Capellá
Journal:  Curr Pharm Des       Date:  2010-01       Impact factor: 3.116

Review 5.  GM-CSF gene-modifed cancer cell immunotherapies: of mice and men.

Authors:  Kristen M Hege; Karin Jooss; Drew Pardoll
Journal:  Int Rev Immunol       Date:  2006 Sep-Dec       Impact factor: 5.311

6.  Adjuvant GM-CSF improves survival in high-risk stage iiic melanoma: a single-center Study.

Authors:  Travis E Grotz; Lisa Kottschade; Emily S Pavey; Svetomir N Markovic; James W Jakub
Journal:  Am J Clin Oncol       Date:  2014-10       Impact factor: 2.339

7.  Comparative antitumor effect among GM-CSF, IL-12 and GM-CSF+IL-12 genetically modified tumor cell vaccines.

Authors:  A Miguel; M J Herrero; L Sendra; R Botella; R Algás; M Sánchez; S F Aliño
Journal:  Cancer Gene Ther       Date:  2013-08-23       Impact factor: 5.987

8.  Perioperative sargramostim (recombinant human GM-CSF) induces an increase in the level of soluble VEGFR1 in colon cancer patients undergoing minimally invasive surgery.

Authors:  I Kirman; A Belizon; E Balik; D Feingold; T Arnell; P Horst; S Kumara; V Cekic; S Jain; A Nasar; R L Whelan
Journal:  Eur J Surg Oncol       Date:  2007-05-18       Impact factor: 4.424

Review 9.  Mesoporous silica nanoparticles in drug delivery and biomedical applications.

Authors:  Ying Wang; Qinfu Zhao; Ning Han; Ling Bai; Jia Li; Jia Liu; Erxi Che; Liang Hu; Qiang Zhang; Tongying Jiang; Siling Wang
Journal:  Nanomedicine       Date:  2014-11-13       Impact factor: 5.307

Review 10.  Use of cytokine therapy in primary immunodeficiency.

Authors:  Sumita Roy-Ghanta; Jordan S Orange
Journal:  Clin Rev Allergy Immunol       Date:  2010-02       Impact factor: 10.817

View more
  5 in total

1.  EB virus-positive tumors are inhibited by rBCG expressing hGM-CSF and LMP2A.

Authors:  Yingchun Yan; Qing-Jie Xue; Ang Liu; Hui Wang; Honghua Zhang; Shuang Wang; Longyu Zhao; Yunqing Li; Xiuzhen Li; Yuanyuan Yang; Ting Chen; Shigen Li
Journal:  Hum Vaccin Immunother       Date:  2019-10-29       Impact factor: 3.452

2.  Human Granulocyte-Macrophage Colony-Stimulating Factor Fused to Elastin-Like Polypeptides Assembles Biologically-Active Nanoparticles.

Authors:  Mincheol Park; Vijaya P Vaikari; Jugal P Dhandhukia; Houda Alachkar; J Andrew MacKay
Journal:  Bioconjug Chem       Date:  2020-05-05       Impact factor: 4.774

Review 3.  The era of bioengineering: how will this affect the next generation of cancer immunotherapy?

Authors:  Michele Graciotti; Cristiana Berti; Harm-Anton Klok; Lana Kandalaft
Journal:  J Transl Med       Date:  2017-06-19       Impact factor: 5.531

Review 4.  Exploring the Potential of Cell-Free Protein Synthesis for Extending the Abilities of Biological Systems.

Authors:  Khushal Khambhati; Gargi Bhattacharjee; Nisarg Gohil; Darren Braddick; Vishwesh Kulkarni; Vijai Singh
Journal:  Front Bioeng Biotechnol       Date:  2019-10-11

Review 5.  Immunomodulation for the Treatment of Fungal Infections: Opportunities and Challenges.

Authors:  Muluneh Ademe
Journal:  Front Cell Infect Microbiol       Date:  2020-09-15       Impact factor: 5.293

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.